Ipilimumab for Patients with Relapse after Allogeneic Transplantation

BACKGROUND: Loss of donor-mediated immune antitumor activity after allogeneic hematopoietic stem-cell transplantation (HSCT) permits relapse of hematologic cancers. We hypothesized that immune checkpoint blockade established by targeting cytotoxic T-lymphocyte–associated protein 4 with ipilimumab co...

詳細記述

保存先:
書誌詳細
出版年:N Engl J Med
主要な著者: Davids, Matthew S., Kim, Haesook T., Bachireddy, Pavan, Costello, Caitlin, Liguori, Rebecca, Savell, Alexandra, Lukez, Alexander P., Avigan, David, Chen, Yi-Bin, McSweeney, Peter, LeBoeuf, Nicole R., Rooney, Michael S., Bowden, Michaela, Zhou, Chensheng W., Granter, Scott R., Hornick, Jason L., Rodig, Scott J., Hirakawa, Masahiro, Severgnini, Mariano, Hodi, F. Stephen, Wu, Catherine J., Ho, Vincent T., Cutler, Corey, Koreth, John, Alyea, Edwin P., Antin, Joseph H., Armand, Philippe, Streicher, Howard, Ball, Edward D., Ritz, Jerome, Bashey, Asad, Soiffer, Robert J.
フォーマット: Artigo
言語:Inglês
出版事項: 2016
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5149459/
https://ncbi.nlm.nih.gov/pubmed/27410923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1601202
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料